Leflunomide is an immunosuppressant medication used in the treatment of rheumatoid arthritis. Leflunomide is rapidly and extensively metabolized to teriflunomide, which is the active form of the medication. Steady state plasma concentrations in patients receiving recommended daily dosages: up to 63,000 ng/mL. It is recommended that all women of childbearing potential who discontinue leflunomide and women receiving treatment who wish to become pregnant undergo the cholestyramine drug elimination procedure. This procedure includes verification that plasma levels of teriflunomide are less than 20 ng/mL by two separate tests at least 14 days apart
1.0 mL Serum from a Red Top Tube in a Plastic Vial
5 days Ambient - Transport
14 days Refrigerated
30 days Frozen
0.5 mL Serum
Mean steady state plasma concentrations of teriflunomide from patients on daily dosages of 5, 10, or 25 mg of leflunomide were 8,800, 18,000 and 63,000 ng/mL, respectively. It is recommended that women of childbearing potential who discontinue leflunomide therapy undergo the cholestyramine drug elimination procedure. This procedure includes verification that plasma levels of teriflunomide are less than 20 ng/mL by two separate tests at least 14 days apart.
Leflunomide is an immunosuppressant medication used in the treatment of rheumatoid arthritis. Leflunomide is rapidly and extensively metabolized to teriflunomide, which is the active form of the medication. Steady state plasma concentrations in patients receiving recommended daily dosages: up to 63,000 ng/mL. It is recommended that all women of childbearing potential who discontinue leflunomide and women receiving treatment who wish to become pregnant undergo the cholestyramine drug elimination procedure. This procedure includes verification that plasma levels of teriflunomide are less than 20 ng/mL by two separate tests at least 14 days apart
3 to 5 days
00913333
80193